Altimmune, Inc. (NASDAQ:ALT) Given Average Recommendation of “Hold” by Analysts

Altimmune, Inc. (NASDAQ:ALT) has received a consensus recommendation of “Hold” from the nine analysts that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $16.60.

A number of analysts recently issued reports on the company. B. Riley Financial dropped their price objective on Altimmune from $18.00 to $13.00 and set a “buy” rating on the stock in a report on Friday. Barclays started coverage on Altimmune in a report on Tuesday, January 27th. They set an “overweight” rating and a $20.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a research report on Monday, December 29th. Wall Street Zen downgraded shares of Altimmune from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Citigroup restated a “market outperform” rating on shares of Altimmune in a research report on Wednesday, November 12th.

Altimmune News Summary

Here are the key news stories impacting Altimmune this week:

• Positive Sentiment: Company advanced pemvidutide development — management reiterated plans to initiate a Phase 3 MASH trial in 2026, pemvidutide received FDA Breakthrough Therapy designation for MASH, and RECLAIM Phase 2 topline data in AUD is expected in 3Q 2026. Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates
• Positive Sentiment: Balance sheet strengthened — company reported about $274M in cash, cash equivalents and short-term investments at year-end and completed a $75M registered direct offering in January, supporting clinical programs and runway. Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates
• Positive Sentiment: Company outlined a large, 1,800‑patient Phase III MASH design and signaled cash runway into 2028 as pemvidutide advances — this reduces near-term execution risk for the lead program. Altimmune outlines 1,800-patient Phase III MASH trial and signals cash runway into 2028
• Neutral Sentiment: B. Riley cut its price target from $18 to $13 but kept a Buy rating — the new target still implies meaningful upside vs. current levels, though it reduces analyst enthusiasm relative to prior coverage. Benzinga
• Neutral Sentiment: Earnings call and transcripts are available for review — useful for investors who want management’s commentary on timelines, trial designs and cash runway. Altimmune Q4 2025 Earnings Call Transcript (Seeking Alpha)
• Neutral Sentiment: Reported short-interest notes appear to show anomalous/zero values in public data feeds and are not a reliable signal at this time.
• Negative Sentiment: Q4 earnings missed estimates — EPS of ($0.27) vs. consensus ($0.25) and immaterial GAAP revenue ($0.03M); very large negative margins and negative ROE highlight ongoing R&D spending and lack of commercial revenue. Altimmune stock edges down on fourth quarter earnings miss

Altimmune Trading Up 0.9%

Shares of ALT stock opened at $3.54 on Friday. The stock has a market capitalization of $399.42 million, a price-to-earnings ratio of -3.50 and a beta of 0.13. The company’s fifty day simple moving average is $4.48 and its two-hundred day simple moving average is $4.29. Altimmune has a 1 year low of $2.90 and a 1 year high of $7.73. The company has a debt-to-equity ratio of 0.08, a current ratio of 17.18 and a quick ratio of 17.18.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.02). The company had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative return on equity of 54.03% and a negative net margin of 214,860.98%. As a group, analysts anticipate that Altimmune will post -1.35 earnings per share for the current year.

Insider Buying and Selling at Altimmune

In other news, Director John Gill purchased 12,500 shares of the firm’s stock in a transaction dated Tuesday, December 23rd. The shares were purchased at an average price of $4.10 per share, with a total value of $51,250.00. Following the completion of the acquisition, the director owned 12,500 shares in the company, valued at $51,250. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Jerome Benedict Durso acquired 12,500 shares of the stock in a transaction that occurred on Monday, December 22nd. The stock was acquired at an average price of $4.13 per share, for a total transaction of $51,625.00. Following the transaction, the director directly owned 12,500 shares of the company’s stock, valued at $51,625. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders acquired 30,527 shares of company stock valued at $125,278. Insiders own 4.40% of the company’s stock.

Hedge Funds Weigh In On Altimmune

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Arax Advisory Partners boosted its position in shares of Altimmune by 99.7% during the 4th quarter. Arax Advisory Partners now owns 8,165 shares of the company’s stock valued at $29,000 after acquiring an additional 4,076 shares during the last quarter. SBI Securities Co. Ltd. increased its position in shares of Altimmune by 27.9% in the fourth quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company’s stock worth $32,000 after purchasing an additional 1,928 shares during the last quarter. Quadrature Capital Ltd purchased a new stake in Altimmune in the fourth quarter valued at approximately $36,000. Victory Capital Management Inc. purchased a new stake in Altimmune in the third quarter valued at approximately $38,000. Finally, CreativeOne Wealth LLC bought a new stake in Altimmune during the fourth quarter valued at approximately $38,000. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.